it sounds like most on the board will vote yes. so maybe this is a moot post. i maintain that we're not going to have any earth-shattering news prior to the vote - but maybe we will - who knows. my 2 points are:

1. the new team is controlling what they can control. they have cut costs on trials (moving toward a partnership approach which will come at some point). they have also cut the marketing costs (although i do miss seeing Christine Corrado ), and have cut compensation costs. in other words, they are running a tight ship financially.

2. what they cannot control is the timing of the clinical hold lift - the FDA has to ulimately clear that, unfortunately, and we know how that beauracracy works. i really hope the FDA doesn't slow walk us on this - but again, we are somewhat at their mercy.

that said, i would love to hear from Cyrus - just to see his face, hear his voice, and see his enthusiasm for our drug and the path forward.